Vaziri-Harami, Roya, Delkash, Parisa · Annals of medicine and surgery (2012) · 2022 · DOI
Some people develop long-lasting fatigue after COVID-19 infection, similar to ME/CFS, and this fatigue can last for months. This article suggests that L-carnitine, a natural substance that helps cells produce energy, might help reduce this type of fatigue based on its success in treating fatigue caused by other diseases like cancer and multiple sclerosis. The authors recommend testing L-carnitine in clinical trials to see if it actually works and is safe for people with post-COVID fatigue.
Post-COVID fatigue affects many patients and remains difficult to treat, with no established standard therapies. If L-carnitine proves effective in clinical trials, it could offer ME/CFS and post-COVID patients a relatively safe, accessible treatment option with a mechanism (supporting cellular energy production) relevant to fatigue pathophysiology.
This review provides no evidence that L-carnitine actually works for post-COVID fatigue or ME/CFS in humans. It does not include any clinical trial data, patient outcomes, or direct testing in post-COVID populations. The suggestion is based on reasoning by analogy from other conditions, which does not establish efficacy or safety in this specific population.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →